Compare FRT & CORT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FRT | CORT |
|---|---|---|
| Founded | 1962 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.4B | 8.6B |
| IPO Year | N/A | N/A |
| Metric | FRT | CORT |
|---|---|---|
| Price | $102.04 | $85.21 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 14 | 6 |
| Target Price | $110.21 | ★ $130.20 |
| AVG Volume (30 Days) | 691.3K | ★ 965.7K |
| Earning Date | 10-31-2025 | 11-04-2025 |
| Dividend Yield | ★ 4.46% | N/A |
| EPS Growth | ★ 14.84 | N/A |
| EPS | ★ 3.95 | 0.87 |
| Revenue | ★ $1,257,396,000.00 | $741,172,000.00 |
| Revenue This Year | $5.51 | $23.79 |
| Revenue Next Year | $5.27 | $40.97 |
| P/E Ratio | ★ $25.69 | $95.90 |
| Revenue Growth | 6.11 | ★ 17.92 |
| 52 Week Low | $80.65 | $49.00 |
| 52 Week High | $113.13 | $117.33 |
| Indicator | FRT | CORT |
|---|---|---|
| Relative Strength Index (RSI) | 64.37 | 57.65 |
| Support Level | $100.00 | $78.07 |
| Resistance Level | $102.81 | $85.34 |
| Average True Range (ATR) | 1.43 | 3.48 |
| MACD | 0.45 | -0.21 |
| Stochastic Oscillator | 85.36 | 65.10 |
Federal Realty Investment Trust is a shopping center-focused retail real estate investment trust that owns high-quality properties in eight of the largest metropolitan markets. Its portfolio includes an interest in 102 properties, which includes 27.4 million square feet of retail space and 3,000 multifamily units. Federal's retail portfolio includes grocery-anchored centers, superregional centers, power centers, and mixed-use urban centers. Federal Realty has focused on owning assets in highly desirable areas with significant growth, and as a result, the average population density and average median household income are higher for its portfolio than for any other retail REIT.
Corcept Therapeutics Inc is a commercial-stage pharmaceutical company engaged in the discovery and development of medications that treat severe metabolic, oncologic and neuropsychiatric disorders by modulating the effect of the hormone cortisol. The company's compounds are being evaluated in clinical trials as potential treatments for a variety of serious disorders - hypercortisolism, advanced ovarian cancer, prostate cancer, ALS, and MASH.